Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure

References

• Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872–1885.
   PubMed Web of Science ®Google Scholar
• Sekeres MA. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Comprehens Cancer Netw: JNCCN. 2011;9:57–63.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Prognosis of myelodysplastic syndromes. Hematol/Educ Prog Am Soc Hematol Am Soc Hematol Educ Prog. 2010;2010:330–337.
   PubMedGoogle Scholar
• Jiang Y, Bonig H, Ulyanova T, et al. On the adaptation of endosteal stem cell niche function in response to stress. Blood. 2009;114:3773–3782.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Park S, Sapena R, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia. 2013;27:1283–1290.
   PubMed Web of Science ®Google Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. JCO. 2014;32:1242–1248.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Othus M, List AF, et al. Additional analyses of a randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American Intergroup Study SWOG S1117. Blood. 2015;126:908.
   Web of Science ®Google Scholar
• Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116:3830–3834.
   PubMed Web of Science ®Google Scholar
• Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. JCO. 2011;29:3322–3327.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Smith BD, Komrokji RS, et al. Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS). Am J Med. 2013;126:e25.
   PubMed Web of Science ®Google Scholar
• Nazha A, Komrokji RS, Garcia-Manero G, et al. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016;101:e224–e227.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. JCO. 2014;32:2691–2698.
   PubMed Web of Science ®Google Scholar
• Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016;30:2214–2220.
   PubMed Web of Science ®Google Scholar
• Nazha A, Seastone D, Keng M, et al. The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. Leuk Lymphoma. 2015;56:3437–3439.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Daver N, Kim H, et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymph Myel Leuk. 2014;14:401–410.
   PubMed Web of Science ®Google Scholar
• Padron E, Garcia-Manero G, Patnaik MM, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5:e333.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. JCO. 2007;25:3503–3510.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351–1361.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Attar E, Bennett JM, et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Comprehens Cancer Netw: JNCCN. 2013;11:838–874.
   PubMed Web of Science ®Google Scholar
• Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. JCO. 2011;29:1963–1970.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Gerds AT, Gooley TA, Wilson WA, et al. Components of the revised International Prognostic Scoring System and outcome after hematopoietic cell transplantation for myelodysplastic syndrome. Blood. 2013;121:4007–4008.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Alessandrino EP, Bacigalupo A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014;123:2333–2342.
   PubMed Web of Science ®Google Scholar
• Voso MT, Fenu S, Latagliata R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. JCO. 2013;31:2671–2677.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Lee JW, Prebet T, et al. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. Br J Haematol. 2014;166:352–359.
   PubMed Web of Science ®Google Scholar
• Lamarque M, Raynaud S, Itzykson R, et al. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood. 2012;120:5084–5085.
   PubMed Web of Science ®Google Scholar
• Breccia M, Salaroli A, Loglisci G, et al. Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine. Ann Hematol. 2013;92:411–412.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Swern AS, Fenaux P, et al. Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). Blood Cancer J. 2014;4:e242.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Sekeres MA, Garcia-Manero G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016;30:649–657.
   PubMed Web of Science ®Google Scholar
• Yahng SA, Jeon YW, Yoon JH, et al. Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome. Bone Marrow Transplant. 2016. DOI:10.1038/bmt.2016.295
   Web of Science ®Google Scholar
• Al-Issa K, Zarzour A, Radivoyevitch T, et al. Incorporation of molecular data into the current prognostic models in treated patients with myelodysplastic syndromes: which model is the best? American Society of Hematology 58th Annual Meeting and Exposition; 2016.
   Google Scholar
• Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114:3448–3458.
   PubMed Web of Science ®Google Scholar
• van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol. 2011;155:599–606.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117:403–411.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Lee JW, Prebet T, et al. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. Br J Haematol. 2014;167:62–68.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007;109:265–273.
   PubMed Web of Science ®Google Scholar
• Wijermans PW, Lubbert M, Verhoef G, et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol. 2005;84:9–17.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–247.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–3627.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384–1395.
   PubMed Web of Science ®Google Scholar
• Haferlach C, Bacher U, Haferlach T, et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. Leukemia. 2011;25:874–877.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Figueroa ME. Interpreting new molecular genetics in myelodysplastic syndromes. Hematol/Educ Prog Am Soc Hematol Am Soc Hematol Educ Prog. 2012;2012:56–64.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Fenaux P. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. Best Pract Res Clin Haematol. 2013;26:355–364.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Komrokji RS. There's risk, and then there's risk: the latest clinical prognostic risk stratification models in myelodysplastic syndromes. Curr Hematol Malig Rep. 2013;8:351–360.
   PubMed Web of Science ®Google Scholar
• Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705–2712.
   PubMed Web of Science ®Google Scholar
• Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28:78–87.
   PubMed Web of Science ®Google Scholar
• Roberts DA, Steensma DP. Outlook and management of patients with myelodysplastic syndromes failed by hypomethylating agents. Curr Hematol Malig Rep. 2015;10:318–328.
   PubMed Web of Science ®Google Scholar
• Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17:5–19.
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Garcia-Manero G, Strati P, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015;121:876–882.
   PubMed Web of Science ®Google Scholar
• Prebet T, Fenaux P, Vey N, et al. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. Haematologica. 2016;101:e427–e428.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Faderl S, Sasaki K, et al. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017;123:629–637.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:496–508.
   PubMed Web of Science ®Google Scholar